Jennie L Conroy
Overview
Explore the profile of Jennie L Conroy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luderman K, Jain P, Free R, Conroy J, Aube J, Sibley D, et al.
Bioorg Med Chem Lett
. 2020 Nov;
31:127696.
PMID: 33221389
MLS1082 is a structurally novel pyrimidone-based D1-like dopamine receptor positive allosteric modulator. Potentiation of D1 dopamine receptor (D1R) signaling is a therapeutic strategy for treating neurocognitive disorders. Here, we investigate...
2.
Luderman K, Conroy J, Free R, Southall N, Ferrer M, Sanchez-Soto M, et al.
Mol Pharmacol
. 2018 Aug;
94(4):1197-1209.
PMID: 30068735
The D dopamine receptor is linked to a variety of neuropsychiatric disorders and represents an attractive drug target for the enhancement of cognition in schizophrenia, Alzheimer disease, and other disorders....
3.
Dix A, Conroy J, George Rosenker K, Sibley D, Appella D
ACS Med Chem Lett
. 2015 Apr;
6(4):425-9.
PMID: 25893044
Peptide nucleic acid scaffolds represent a promising tool to interrogate the multivalent effects of ligand binding to a membrane receptor. Dopamine D2 receptors (D2R) are a class of G-protein coupled...
4.
Conroy J, Free R, Sibley D
ACS Chem Neurosci
. 2015 Feb;
6(4):681-92.
PMID: 25660762
The D1 dopamine receptor (D1R) has been implicated in numerous neuropsychiatric disorders, and D1R-selective ligands have potential as therapeutic agents. Previous studies have identified substituted benzazepines as D1R-selective agonists, but...
5.
Meade J, Free R, Miller N, Chun L, Doyle T, Moritz A, et al.
Psychopharmacology (Berl)
. 2014 Sep;
232(5):917-30.
PMID: 25231919
Rationale: (-)-Stepholidine is a tetrahydroberberine alkaloid that is known to interact with dopamine receptors and has also been proposed as a novel antipsychotic agent. Its suggested novelty lies in the...
6.
Free R, Chun L, Moritz A, Miller B, Doyle T, Conroy J, et al.
Mol Pharmacol
. 2014 Apr;
86(1):96-105.
PMID: 24755247
A high-throughput screening campaign was conducted to interrogate a 380,000+ small-molecule library for novel D2 dopamine receptor modulators using a calcium mobilization assay. Active agonist compounds from the primary screen...
7.
Xiao J, Free R, Barnaeva E, Conroy J, Doyle T, Miller B, et al.
J Med Chem
. 2014 Mar;
57(8):3450-63.
PMID: 24666157
The D2 dopamine receptor (D2 DAR) is one of the most validated drug targets for neuropsychiatric and endocrine disorders. However, clinically approved drugs targeting D2 DAR display poor selectivity between...
8.
Conroy J, Nalwalk J, Phillips J, Hough L
Brain Res
. 2013 Jan;
1499:1-11.
PMID: 23298831
Brain cytochrome P450 epoxygenases were recently shown to play an essential role in mediating the pain-relieving properties of morphine. To identify the CNS sites containing the morphine-relevant P450s, the effects...
9.
Bergman J, Roof R, Furman C, Conroy J, Mello N, Sibley D, et al.
Int J Neuropsychopharmacol
. 2012 Jul;
16(2):445-58.
PMID: 22827916
Converging lines of evidence indicate that elevations in synaptic dopamine levels play a pivotal role in the reinforcing effects of cocaine, which are associated with its abuse liability. This evidence...
10.
Hough L, Nalwalk J, Yang J, Conroy J, VanAlstine M, Yang W, et al.
Pain
. 2011 Feb;
152(4):878-887.
PMID: 21316152
The search for the mechanism of action of improgan (a nonopioid analgesic) led to the recent discovery of CC12, a compound that blocks improgan antinociception. Because CC12 is a cytochrome...